Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 14/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.43 |
| ▸ | USP2 | O75604 | 9/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26524427 | 0.91 | CYP2D6 (0.45) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL24607443 | 0.90 | CYP2D6 (0.48) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL26445329 | 0.89 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL26445336 | 0.89 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL23560349 | 0.88 | CYP2D6 (0.58) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL18926698 | 0.88 | CYP2D6 (0.56) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL18212474 | 0.88 | CYP2D6 (0.52) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL24751941 | 0.84 | CYP3A4 (0.51) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL13400658 | 0.84 | CYP3A4 (0.51) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL19969931 | 0.82 | CYP3A4 (0.50) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024077023-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CYP2D6 474/4885SMN1; SMN2 3385/4885CYP3A4 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.